Patents Assigned to Genexine Co., Ltd.
-
Publication number: 20130195905Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.Type: ApplicationFiled: August 13, 2010Publication date: August 1, 2013Applicants: BIOD CO., LTD., GENEXINE CO., LTD.Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
-
Publication number: 20120276097Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: ApplicationFiled: June 11, 2012Publication date: November 1, 2012Applicants: POSTECH Academy-Industry Foundation of Pohang University of Science and Technology (POSTECH), Genexine Co., Ltd.Inventors: Sehwan YANG, Young Chul Sung
-
Publication number: 20120276096Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: ApplicationFiled: June 11, 2012Publication date: November 1, 2012Applicants: POSTECH Academy-Industry Foundation of Pohang University of Science and Technology (POSTECH), Genexine Co., LtdInventors: Sehwan YANG, Young Chul Sung
-
Publication number: 20120276043Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: ApplicationFiled: June 11, 2012Publication date: November 1, 2012Applicants: POSTECH Academy-Industry Foundation of Pohang University of Science & Technology (POSTECH, Genexine Co., LtdInventors: Sehwan YANG, Young Chul Sung
-
Patent number: 8137674Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.Type: GrantFiled: April 19, 2006Date of Patent: March 20, 2012Assignees: Postech Foundation, Genexine Co., Ltd.Inventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn
-
Publication number: 20110091416Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: ApplicationFiled: November 19, 2010Publication date: April 21, 2011Applicants: Genexine Co., Ltd, POSTECH Academy-Industry Foundation of Pohang University of Science and Technology ( POSTECH)Inventors: Sehwan YANG, Young Chul Sung
-
Patent number: 7910564Abstract: The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12 (interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL- 12p70 by making mutation at Asn-222 (human) or Asn- 220 (mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.Type: GrantFiled: August 2, 2007Date of Patent: March 22, 2011Assignee: Genexine Co., Ltd.Inventors: Young Chul Sung, Sung Hee Lee, Sang Jun Ha, Man Ki Song, Jun Chang
-
Patent number: 7867491Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: May 30, 2008Date of Patent: January 11, 2011Assignees: Genexine Co., Ltd., Postech Academy-Industry Foundation of Pohang University of Science and TechnologyInventors: Sehwan Yang, Young Chul Sung
-
Publication number: 20090305979Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.Type: ApplicationFiled: April 19, 2006Publication date: December 10, 2009Applicants: POSTECH FOUNDATION, GENEXINE CO., LTDInventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn
-
Publication number: 20080300188Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: ApplicationFiled: May 30, 2008Publication date: December 4, 2008Applicants: Genexine Co., Ltd, POSTECH Academy-Industry Foundation of PohangInventors: Sehwan Yang, Young Chul Sung
-
Patent number: 7253151Abstract: The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12(interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL-12p70 by making mutation at Asn-222(human) or Asn-220(mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.Type: GrantFiled: March 15, 2001Date of Patent: August 7, 2007Assignee: Genexine Co., Ltd.Inventors: Young Chul Sung, Sung Hee Lee, Sang Jun Ha, Man Ki Song, Jun Chang
-
Patent number: 6818442Abstract: The present invention relates to a plasmid carrying simian immunodeficiency virus (SIV)-derived genes. Particularly, the present invention relates to the plasmid pSIV/GE which carrys gag, protease, env and rev gene, all derived from SIV, but not tat and nef gene and the plasmid pSIV/pol which carrys SIV-derived pol gene; the plasmid pHIV/GE and pHIV/pol that are substituted the SIV-derived genes in the plasmid pSIV/GE and pSIV/pol by human immunodeficiency virus (HIV)-derived corresponding genes; DNA vaccine containing the plasmid pSIV/GE and pSIV/pol; and DNA vaccine containing the plasmid pHIV/GE and pHIV/pol. The present invention offers AIDS DNA vaccines which successfully exert perfect medicinal efficacy on primates, giving a measure of success in developing effective AIDS DNA vaccines applicable to humans. The plasmid of the present invention can be effectively used for not only AIDS prevention by AIDS infection but also therapeutic agent for AIDS.Type: GrantFiled: December 6, 2000Date of Patent: November 16, 2004Assignees: Genexine Co. Ltd., Pohang University of Science and TechnologyInventors: Young Chul Sung, You Suk Suh